Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1249-1260

  Kowshika, Jaganathan ^a   Girib, Hemant ^b   Kishore, Tanagala Kranthi Kiran ^a   Kesavan, Rushendhiran ^b   Vankudavathc, Raju Naik ^c   Reddyd, Geereddy Bhanuprakash ^c   Dixitb, Madhulika ^b   Naginia, Siddavaram ^a  

^a ANNAMALAI UNIVERSITY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^c NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

Angiogenesis; Ellagic acid; Hamster buccal pouch; Histone deacetylases; Protein kinases; Vascular endothelial growth factor

Indexed keywords

ELLAGIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANGIOGENESIS INHIBITOR; HISTONE DEACETYLASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOGENESIS; CELL HYPOXIA; CELL LINE; CHEEK; CHEMICALLY INDUCED; DRUG EFFECTS; ENDOTHELIUM CELL; MESOCRICETUS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOGENESIS; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CHEEK; ELLAGIC ACID; ENDOTHELIAL CELLS; HISTONE DEACETYLASES; MALE; MESOCRICETUS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR DOCKING SIMULATION; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84911471304     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140723114217     Document Type: Article

References (50)

1. Shojaei, F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett., 2012, 320, 130-137.
2. Khoury, C.C.; Ziyadeh, F.N. Angiogenic factors. Contrib. Nephrol., 2011, 170, 83-92.
3. Roskoski, Jr. R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol., 2007, 62, 179-213.
4. Eichmann, A.; Simons, M. VEGF signaling inside vascular endothelial cells and beyond. Curr. Opin. Cell Biol., 2012, 24, 188-193.
5. Gacche, R.N.; Meshram, R.J. Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim. Biophys. Acta, 2014, 1846, 161-179.
6. Rhim, T.; Lee, D.Y.; Lee, M. Hypoxia as a target for tissue specific gene therapy. J. Contr. Rel., 2013, 172, 484-94.
7. Graupera, M.; Potente, M. Regulation of angiogenesis by PI3K signaling networks. Exp. Cell Res., 2013, 319, 1348-1355. Anti-Cancer Agents in Medicinal Chemistry, 2014, Vol. 14, No. 9 1259
8. Cossa, G.; Gatti, L.; Cassinelli, G.; Lanzi, C.; Zaffaroni, N.; Perego, P. Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr. Pharm. Des., 2013, 19, 883-94.
9. Cai, T.Y.; Liu, X.W.; Zhu, H.; Cao, J.; Zhang, J.; Ding, L.; Lou, JS.; He, Q.J.; Yang, B. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol. Cancer Ther., 2014, 13, 630-42.
10. Liu, X.W.; Cai, T.Y.; Zhu, H.; Cao, J.; Su, Y.; Hu, Y.Z.; He, Q.J.; Yang, B. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy, 2014, 10, 111-22.
11. Pedram, A.; Razandi, M.; Levin, E.R. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J. Biol. Chem., 1998, 273, 26722-26728.
12. Abid, M.R.; Guo, S.; Minami, T.; Spokes, K.C.; Ueki, K.; Skurk, C.; Walsh, K.; Aird, W.C. Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 294-300.
13. Das, B.; Yeger, H.; Tsuchida, R.; Torkin, R.; Gee, M.F.; Thorner, P.S.; Shibuya, M.; Malkin, D.; Baruchel, S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res., 2005, 65, 7267-7275.
14. Witt, O.; Deubzer, HE.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets?. Cancer Lett., 2009, 277, 8-21.
15. Landete, J.M. Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health. Food Res. Int., 2011, 44, 1150-1160.
16. Bell, C.; Hawthorne, S. Ellagic acid, pomegranate and prostate cancer -a mini review. J. Pharm. Pharmacol., 2008, 60, 139-144.
17. Vidya Priyadarsini, R.; Kumar, N.; Khan, I.; Thiyagarajan, P.; Kondaiah, P.; Nagini, S. Gene expression signature of DMBA-induced hamster buccal carcinomas: Modulation by chlorophyllin and ellagic acid. PLoS One, 2012, 7, e34628.
18. Anitha, P.; Priyadarsini, R.V.; Kavitha, K.; Thiyagarajan, P.; Nagini, S. Ellagic acid coordinately attenuates Wnt/β-catenin and NF-κB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. Eur. J. Nutr., 2013, 52, 75-84.
19. Shklar, G. Development of experimental oral carcinogenesis and its impact on current oral cancer research. J. Dent. Res., 1999, 78, 1768-1772.
20. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 1987, 162, 156-159.
21. Legrand-Poels, S.; Schoonbrodt, S.; Piette, J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem. J., 2000, 349, 765-773.
22. Wang, N.; Wang, Z.Y.; Mo, S.L.; Loo, T.Y.; Wang, D.M.; Luo, H.B.; Yang, D.P.; Chen, Y.L.; Shen, J.G.; Chen, J.P. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res. Treat., 2012, 134, 943-955.
23. Losso, J.N.; Bansode, R.R.; Trappey, A.; Bawadi, H.A.; Truax, R. In vitro anti-proliferative activities of ellagic acid. J. Nutr. Biochem., 2004, 15, 672-678.
24. Constantinou, A.; Stoner, G.D.; Mehta, R.; Rao, K.; Runyan, C.; Moon, R. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutr. Cancer, 1995, 23, 121-130.
25. Umesalma, S.; Sudhandiran, G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur. J. Pharmacol., 2011, 660, 249-258.
26. Kumar, K.N; Raja, S.B.; Vidhya, N.; Devaraj, S.N. Ellagic acid modulates antioxidant status, ornithine decarboxylase expression, and aberrant crypt foci progression in 1,2-dimethylhydrazine-instigated colon preneoplastic lesions in rats. J. Agric. Food Chem., 2012, 60, 3665-3672.
27. Vadhanam, M.V.; Ravoori, S.; Aqil, F.; Gupta, R.C. Chemo-prevention of mammary carcinogenesis by sustained systemic delivery of ellagic acid. Eur. J. Cancer Prev., 2011, 20, 484-491.
28. Cidado, J.; Park, B.H. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J. Mammary Gland Biol. Neoplasia, 2012, 17, 205-216. 1260 Anti-Cancer Agents in Medicinal Chemistry, 2014, Vol. 14, No. 9
29. Papadimitrakopoulou, V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J. Thorac. Oncol., 2012, 7, 1315-1326.
30. Barrett, D.; Brown, V.I.; Grupp, S.A.; Teachey, D.T. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs, 2012, 14, 299-316.
31. Bendell, J.C.; Rodon, J.; Burris, H.A.; De Jonge, M.; Verweij, J.; Birle, D.; Demanse, D.; De Buck, S.S.; Ru, Q.C.; Peters, M.; Goldbrunner, M.; Baselga, J. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol., 2012, 30, 282-290.
32. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J.L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68, 8022-8030.
33. Raynaud, F.I.; Eccles, S.A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A.T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N.C.; Clarke, P.A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther., 2009, 8, 1725-1738.
34. De Luca, A.; Maiello, M.R.; D'Alessio, A.; Pergameno, M.; Normanno, N. The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Exp. Opin. Ther. Targets, 2012, 16, 17-27.
35. Aksamitiene, E.; Kiyatkin, A.; Kholodenko, B.N. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem. Soc. Trans., 2012, 40, 139-146.
36. Wang, X.; Hao, J.; Metzger, D.L.; Ao, Z.; Chen, L.; Ou, D.; Verchere, C.B.; Mui, A.; Warnock, G.L. B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation. PLoS One, 2012, 7, e28232.
37. Nelson, J.M.; Fry, D.W. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem., 2001, 276, 14842-14847.
38. Mudgett, J.S.; Ding, J.; Guh-Siesel, L.; Chartrain, N.A.; Yang, L.; Gopal, S.; Shen, M.M. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc. Natl. Acad. Sci. USA, 2000, 97, 10454-10459.
39. Lee, H.; Jung, K.H.; Jeong, Y.; Hong, S.; Hong, S.S. HS-173, A novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett., 2013, 328, 152-159.
40. Trisciuoglio, D.; Lervolino, A.; Zupi, G.; Del Bufalo, D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol. Biol. Cell, 2005, 16, 4153-4162.
41. Luangdilok, S.; Box, C.; Harrington, K.; Rhŷs-Evans, P.; Eccles, S. MAPK and PI3K signaling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur. J. Cancer, 2011, 47, 520-529.
42. Richard, D.E.; Berra, E.; Gothie, E.; Roux, D.; Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem., 1999, 274, 32631-32637.
43. Hudson, C.C.; Liu, M.; Chiang, C.G.; Otterness, D.M.; Loomis, D.C.; Kaper, F.; Giaccia, A.J.; Abraham, R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 2002, 22, 7004-7014.
44. Garcia-Echeverri, C.; Sellers, W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008, 27, 5511-5526.
45. Qian, C.; Lai, C.J.; Bao, R.; Wang, D.G.; Wang, J.; Xu, G.X.; Atoyan, R.; Qu, H.; Yin, L.; Samson, M.; Zifcak, B.; Ma, A.W.S.; DellaRocca, S.; Borek, M.; Zhai, H.; Cai, X.; Voi, M. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signalling. Clin. Cancer Res., 2012, 18, 4104-4113.
46. Lee, Y.S.; Lim, K.H., Guo, X., Kawaguchi, Y.; Gao, Y.; Barrientos, T.; Ordentlich, P.; Wang, X.F.; Counter, C.M.; Yao, T.P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res., 2008, 68, 7561-7569.
47. Naldini, A.; Filippi, I.; Cini, E.; Rodriquez, M.; Carraro, F.; Taddei, M. Downregulation of hypoxia-related responses by novel antitumor histone deacetylase inhibitors in MDAMB231 breast cancer cells. Anticancer Agents Med. Chem., 2012, 12, 407-413.
48. Kang, F.W.; Que, L.; Wu, M.; Wang, Z.L.; Sun, J. Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol. Rep., 2012, 28, 193-199.
49. Osuka, S.; Takano, S.; Watanabe, S.; Ishikawa, E.; Yamamoto, T.; Matsumura, A. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol. Med. Chir., 2012, 52, 186-193.
50. Aldana-Masangkay, G.I.; Sakamoto, K.M. The role of HDAC6 in cancer. J. Biomed. Biotechnol., 2011, 875-824.